This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Rituximab Plus Lenalidomide Combination Therapy fo...
Clinical trial

Rituximab Plus Lenalidomide Combination Therapy for Patients With Relapsed / Refractory Indolent Non-Hodgkin Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) (AUGMENT)

Read time: 1 mins
Last updated:5th Sep 2013
This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab (MabThera/Rituxan) in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma. Patients will be randomized to receive either lenalidomide or placebo for twelve 28-day cycles in combination with rituximab. Anticipated time on study treatment is 1 year.
Category Value
Study start date 2013-09-05

View full details